Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,023 public trials 2,029 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Screening to Improve Survival in AL Amyloidosis

NCT04615572

Conditions
Amyloidosis, Blood Protein Disorders, Hematologic Diseases, +16 more
Locations
  • University of California, Irvine Health Chao Family Comprehensive Cancer Center Orange, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • University of Miami Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • Tufts Medical Center Boston, Massachusetts, United States
View Trial Details
Completed

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

NCT03846427

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Clinical Research Alliance, Inc Westbury, New York, United States
  • The Charlotte Mecklenburg Hospital Authority Charlotte, North Carolina, United States
  • Canberra Hospital Garran, Australian Capital Territory, Australia
  • Concord Repatriation General Hospital Concord, New South Wales, Australia
View all 31 locations
View Trial Details
Completed

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

NCT03053440

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 58 locations
View Trial Details
Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

NCT03493451

Conditions
ALK-Positive Anaplastic Large Cell Lymphoma, ALK-negative Anaplastic Large Cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, +36 more
Locations
  • British Columbia Cancer Agency the Vancouver Centre Vancouver, British Columbia, Canada
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
View all 24 locations
View Trial Details
Completed

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

NCT02569476

Conditions
B-cell Lymphoid Malignancies, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Florida Cancer Specialists Fort Myers Fort Myers, Florida, United States
  • Florida Cancer Specialists East West Palm Beach, Florida, United States
  • Tennessee Oncology Nashville, Tennessee, United States
  • St George Hospital Kogarah, New South Wales, Australia
View all 14 locations
View Trial Details
Completed

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

NCT03955783

Conditions
Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma, Hematologic Diseases, +15 more
Locations
  • Roswell Park Cancer Center Buffalo, New York, United States
  • University Hospitals of Cleveland Cleveland, Ohio, United States
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
  • University of Texas Southwestern Medical Center Dallas, Texas, United States
View Trial Details
Completed

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT03206970

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
View all 13 locations
View Trial Details

Related conditions